Novel Therapies for Acinetobacter Osteomyelitis
Abstract
It has been well established from current causulty data of our military operations in the Middle East that the ratio of serious injuries to fatal casualties far exceeds that of previous conflicts. Among these serious injuries, war wound infection and osteomyelitis (OM) appear to be of greatest concern. Most alarming is the incidence of multidrug-resistant (MDR) Acinetobacter species. This comes as a major surprise since this pathogen has been reported in less than 2% of nosocomial infections within the United States, but has emerged in over 30% of admitted deployed soldiers. An additional problem is that while there are some effective antibiotics against Acinetobacter (i.e. Colistin and Imipenem), they are not available in bone void fillers that are primarily used to treat OM caused by Staphylococcus. To address this urgent need we propose a collaboration that will take advantage of the first quantitative animal model of implant-associated OM developed for Staphylococcus, and clinical isolates of MDR Acinetobacter obtained from our soldiers. To achieve these goals we will test the hypotheses that: 1) prophylatic chemotherapy with Acinetobacter-specific antibiotics can prevent the establishment of Acinetobacter OM; 2) incorporation of Acinetobacter-specific antibiotics into polymethylmethacrylate bone void filler prevents OM in a contaminated wound; and 3) specific antibodies are raised against common immuno-dominant antigens during the establishment of Acinetobacter OM.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2009
- Accession Number
- ADA493723
Entities
People
- Edward M. Schwarz
Organizations
- University of Rochester